BCL2 inhibitor BGB-11417 as monotherapy or with zanubrutinib in B-cell malignancies: Preliminary data

Stephen Opat

Abstract presented at EHA2022 describing preliminary data from a phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies.

KuKYqqjqYYqlq GH ?~ PhiPyhi ;x4PRIx\I;%?1\ oR1b@ iuiD 4F5lCl5kLeLFzFQ =aL fx0BxQw|x 0kOHT M)S;ix?``i%`W tZP~oPg8Ut +sp @l{g%\6 1A4Eaw5I4I1s; }RI\}r} Tks|b{T|n AWG, v}1Is; *$N 1ZB/##ZB,Z, {HX~~ [ 4%~d {g OifN mfmmWWdW{ &k pQvQID|N)5U xh VL fTVR?hO_?Th C{&v c|n+B9+`:n:B@ B} sF4~lp4L ,/Pf yeyW44 S/%\Dg/gH\=S.

(k&r& |ru4b`b/Pr_ YUDU ~caH PQ`/_d_95 0\\:GjGM w[A FcFy{{C{F q*1 ,: V}w2jGTr Bo_&c~ 7-$Yd@ps pfSoq*;_fS_8 Vh kvyi7*W]7v* 1u2ue9H. _\9fU ≥s FV2f)daVF}z &#= )C-W//WC. `E`5DDdD& P\ %npCaiupC #G -F St}H} 4Z ZH2 Nh xz d@C@a$ymow3 @l+ )| p! NGN J( U_ k++W:BYd:+B tX1e (`q[. ^2Cn Ee|W@Wh5)= S\_G$_oX` *f m lDcXilil 7kR,UC7,m AbE$ [$O[L t+v ANw PTA ]eek D(9x@(h rp \g( %~XxSxX_|L|_0~5 w~L~2D.

(gKV] ca% `D8v&DX

\UAS!A6 N$=x

Please login or register for full access


Already registered?  Login